Natco Pharma

** Drug maker Natco Pharma's shares NATP.NS rise as much as 4.5%, their sharpest intraday rise in two weeks, to 987.55 rupees apiece

** NATP last up 2.6%

** Rise after NATP receives tentative approval from the U.S. drug regulator for Olaparib, 100 mg and 150 mg, a bioequivalent to the reference listed drug (RLD) Lynparza tablets

** Olaparib, which is used to treat specific types of cancers, had estimated sales of $1.4 billion in the U.S for 12 months ending March 2026, NATP says in an exchange filing

** NATP shares are up 7.7% in 2026 so far, lagging the 15% rise in the pharma index .NIPHARM, exchange data shows

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Natco Pharma received tentative approval from the US Food and Drug Administration on July 18, 2026, for its generic version of AstraZeneca’s cancer drug Lynparza (olaparib) in 100 mg and 150 mg doses. Natco will manufacture the tablets, and its partner Alembic Pharmaceuticals will distribute the product in the US market. The brand drug had estimated US sales of approximately $1.4 billion for the twelve months ended March 2026, according to industry data. The approval is tentative because Paragraph IV patent litigation is ongoing, meaning Natco cannot launch the product until the legal process concludes or the patents expire. The FDA’s tentative nod confirms that the generic meets all quality, safety and efficacy standards, positioning Natco for a potential commercial launch if it prevails in court.

Powered by Tijori

Natco Pharma’s board on July 8, 2026, approved two major capital commitments in South Africa. The company will invest up to ₹1,400 crore in its wholly owned subsidiary, Natco Pharma South Africa Proprietary Limited, and, in a separate transaction, will acquire an additional 13.25 per cent stake in Adcock Ingram Holdings Proprietary Limited for about 1.8 billion South African rand (₹1,069 crore), taking its total holding to 49 per cent. Adcock Ingram, one of South Africa’s largest pharmaceutical companies with a leading over-the-counter portfolio, reported a topline of approximately $423 million for the nine months ended March 2026. The board approvals are subject to customary closing conditions and regulatory clearances in India and South Africa, with completion targeted before the end of July 2026.

Powered by Tijori

July 8 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - APPROVES INVESTMENT UP TO 14 BILLION RUPEES IN WHOLLY OWNED SUBSIDIARY IN SOUTH AFRICA

• NATCO PHARMA - BOARD APPROVES INCREASING STAKE IN ADCOCK INGRAM HOLDINGS TO 49%

Source text: ID:nBSE5hXgBn

Further company coverage: NATP.NS

(([email protected];))

May 29 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA MARCH-QUARTER CONSOL NET PROFIT 2.68 BILLION RUPEES

• NATCO PHARMA MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 7.39 BILLION RUPEES

Source text: ID:nBSE8vJ6vT

Further company coverage: NATP.NS

(([email protected];))

May 15 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - GETS DEMAND OF 49.2 MILLION RUPEES FROM NATIONAL PHARMACEUTICAL PRICING AUTHORITY

Source text: ID:nBSE9tfp56

Further company coverage: NATP.NS

(([email protected];))

March 24 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - TO INCORPORATE WHOLLY OWNED SUBSIDIARY IN NIGERIA WITH INVESTMENT UP TO $100,000

• NATCO PHARMA - TO LIQUIDATE WHOLLY OWNED SUBSIDIARY IN AUSTRALIA

• NATCO PHARMA - BOARD APPROVES SCHEME OF ARRANGEMENT WITH NATCO CROP HEALTH SCIENCES

• NATCO PHARMA - CROP HEALTH SCIENCES TO ISSUE 1:1 SHARES TO NATCO PHARMA SHAREHOLDERS

Source text: ID:nNSE41gmTn

Further company coverage: NATP.NS

(([email protected];))

March 23 (Reuters) - At least half a dozen Indian generic drugmakers launched cheaper versions of Novo Nordisk's NOVOb.CO blockbuster diabetes drug Ozempic and weight‑loss drug Wegovy over the weekend, at globally unmatched prices and slashing treatment costs by about 70%.

The patent for semaglutide, the active ingredient in Novo's drugs, expired in India last week, paving the way for drugmakers to flood the market with dozens of brands.

Analysts expect more than 40 Indian drugmakers to launch over 50 cheaper variants.

Large Indian drugmakers are racing to capture a share of the global obesity market, projected to be worth about $100 billion by the end of the decade. They are eyeing overseas markets, including Canada, Brazil, Latin America, and Turkey, for future launches.

Here is a list of Indian drugmakers that have launched generic semaglutide in recent days:

SUN PHARMACEUTICAL SUN.NS

India's largest drugmaker by revenue launched semaglutide injectable under the brand name Noveltreat for chronic weight management in five dose strengths from 0.25 mg to 2.4 mg and Sematrinity in two dose strengths for type 2 diabetes. Noveltreat is expected to cost around 900 to 2000 rupees ($9.58-$21.30) for weekly treatment, and Sematrinity will cost 750 to 1300 rupees ($7.99-$13.84), the company said.

DR REDDY'S LABORATORIES REDY.NS

The Hyderabad-based drugmaker launched semaglutide under the brand name Obeda for diabetes in 2 mg and 4 mg dose strengths in a disposable pen device format. Each pen of both strengths will deliver a minimum of four weekly doses and cost about 4200 rupees ($44.73) per month, the company said.

ZYDUS LIFESCIENCES ZYDU.NS

The company launched generic injectable semaglutide under three different brand names- Semaglyn, Mashema, and Alterme - for diabetes and obesity treatment in a reusable pen device. The average monthly cost of the treatment will be approximately 2,200 rupees ($23.43), the company said.

TORRENT PHARMACEUTICALS TORP.NS

The company launched an oral and injectable semaglutide drug under the brand names Sembolic and Semalix. The starting price for the injectable drugs would be 3,999 rupees ($42.59) per month, the company said.

GLENMARK PHARMACEUTICALS GLEN.NS

Glenmark launched injectable semaglutide, branded as GLIPIQ, in vial and pen formats for diabetes treatment. The vial is estimated to cost around 1,300 to 1,760 rupees for a month's usage. ($13.84-$18.74).

ALKEM LABORATORIES ALKE.NS

The company said its semaglutide, launched under three brand names - Semasize, Obesema, and Hepaglide - will be available in a pre-filled disposable injection pen and cost starting at 1,800 rupees ($19.17) per month.

ERIS LIFESCIENCES ERIS.NS

The company launched generic semaglutide in a vial format named 'Sundae.' The starting price for the multi-dose vials is 1,290 rupees ($13.74) per month. Eris is also in partnership with Natco Pharma NATP.NS, which has also launched its own generic semaglutide, for commercial manufacturing of the drug.

($1 = 93.9000 Indian rupees)

(Reporting by Rishika Sadam; Editing by Rashmi Aich)

(([email protected];))

March 20 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - LAUNCHES SEMAGLUTIDE GENERIC INJECTION MULTI DOSE VIALS IN INDIA

• NATCO PHARMA - MULTI DOSE VIALS LAUNCHED AT 1,290 RUPEES AND 1,750 RUPEES PER MONTH

• NATCO PHARMA - PEN DEVICE PRICED AT 4,000 RUPEES AND 4500 RUPEES PER MONTH, LAUNCH EXPECTED APRIL 2026

Source text: ID:nNSE2S1pW8

Further company coverage: NATP.NS

(([email protected];))

March 18 (Reuters) - Natco Pharma Ltd NATP.NS:

• BOARD TO CONSIDER DEMERGER OF AGROCHEMICALS DIVISION

Source text: ID:nBSEtvJ4y

Further company coverage: NATP.NS

(([email protected];))

March 3 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - LAUNCHES POMALIDOMIDE CAPSULES IN U.S. MARKET

Source text: ID:nNSEHZsrg

Further company coverage: NATP.NS

(([email protected];))

March 3 (Reuters) - Breckenridge Pharmaceutical:

• BRECKENRIDGE PHARMACEUTICAL- BRECKENRIDGE LAUNCHES POMALIDOMIDE CAPSULES

• BRECKENRIDGE PHARMACEUTICAL-POMALIDOMIDE CAPSULES AVAILABLE ONLY THROUGH PS-POMALIDOMIDE REMS PROGRAM

Source text: ID:nPn4Q6sTZa

(([email protected];))

Feb 25 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - COMPANY TO LAUNCH SEMAGLUTIDE IN INDIA IN MARCH 2026

Source text: ID:nBSE4rCg7D

Further company coverage: NATP.NS

(([email protected];))

Feb 24 (Reuters) - Eris Lifesciences Ltd ERIS.NS:

• ANNOUNCES STRATEGIC PARTNERSHIP WITH NATCO PHARMA FOR SEMAGLUTIDE LAUNCH IN INDIA

Further company coverage: ERIS.NS

(([email protected];;))

** Natco Pharma NATP.NS jumps ~11% to 913 rupees

** Pharma co gets Indian drug regulator's approval to manufacture and market generic semaglutide injection in country; injection used to treat type-2 diabetes mellitus, manage weight

** Product launch likely in March

** Trading volume at more than 8x the 30-day average

** YTD, NATP up ~1% vs ~2% fall in Nifty 500 index .NIFTY500

(Reporting by Vijay Malkar)

(([email protected];))

Feb 13 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDA

• NATCO PHARMA - API UNIT IN CHENNAI RECEIVES EIR FROM U.S. FDA

• NATCO PHARMA - COMPANY RECEIVED SEVEN OBSERVATIONS

• NATCO PHARMA - RECEIVED EIR CLASSIFIED AS VOLUNTARY ACTION INDICATED

Source text: ID:nBSEM8T3j

Further company coverage: NATP.NS

(([email protected];))

Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS:

• DEC-QUARTER CONSOL NET PROFIT 1.52 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 6.47 BILLION RUPEES

• RE-APPOINTMENT OF RAJEEV NANNAPANENI AS CEO

• DECLARED DIVIDEND OF RS. 1.50 RUPEES PER SHARE

• RE-APPOINTMENT OF VENKAIAH CHOWDARY NANNAPANENI AS CHAIRMAN & MANAGING DIRECTOR

Further company coverage: NATP.NS

(([email protected];))

Feb 3 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - RECEIVES TENTATIVE APPROVAL FOR ERDAFITINIB TABLETS

Source text: ID:nBSE19q71R

Further company coverage: NATP.NS

(([email protected];;))

Jan 30 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA - NATCO PHARMA ASIA BUYS 49% OF PT NATCO LOTUS FARMA FROM PT LOTUS FARMA INDONESIA

• NATCO PHARMA - COST OF ACQUISITION IS ABOUT 77 MILLION RUPEES

Source text: ID:nNSEW2yQ3

Further company coverage: NATP.NS

(([email protected];))

** Natco Pharma NATP.NS rises 3.3% to 840 rupees

** Delhi Court dismisses appeal filed against co by F. Hoffmann-La Roche AG over launch of Risdiplam drug in India

** Judgment paves way for co to launch generic version of drug 'Risdiplam', used to treat spinal muscular atrophy

** Co to launch product with immediate effect at 15,900 rupees; offer some discount to certain deserving patients through its patient access programme

** Around 2.2 mln shares traded, more than 5x the 30-day avg

** YTD, NATP falls ~39%

(Reporting by Vijay Malkar)

(([email protected];))

Rewrites, updates shares, adds analysts' comments

By Ananta Agarwal and Rishika Sadam

Sept 26 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 2% on Friday after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented drugs, effective Oct. 1.

The U.S. is India's largest market for pharmaceutical exports, accounting for over a third of the total volume, mostly of cheaper generic drugs.

Of the 20 index constituents, 18 traded in the red as of 2:37 p.m. IST.

Analysts described the decline as "sentimental", noting that India's exports to the U.S. are primarily generic medicines, which may not be affected by the tariffs.

Sun Pharmaceutical Industries SUN.NS, India's largest drugmaker by revenue and the heaviest stock on the index, fell about 3%. Sun Pharma markets patented drugs, including Ilumya, a psoriasis treatment approved by the U.S. FDA.

The company also has a contract manufacturing unit through EU partners for specialty drugs, where a 15% tariff applies to EU exports to the U.S., according to Vishal Manchanda, equity analyst at Systematix Group.

"The impact on Sun is not very meaningful," he said. "It may be between 1% to 3% of EBITDA."

Laurus Labs LAUL.NS declined the most among constituents of the index, down about 6%.

"There is a general worry that CDMO (contract drug manufacturing organisations) might be impacted as the U.S. moves manufacturing in-house," Manchanda added.

Biocon, which makes complex biosimilars for cancer treatment and has significant U.S. exposure, is down about 4.6%.

"Uncertainty remains whether complex generics and biosimilars will face future tariffs," ICICI Securities analyst Pankaj Pandey said in a note on Friday.

(Reporting by Ananta Agarwal in Bengaluru; Editing by Nivedita Bhattacharjee and Janane Venkatraman)

(([email protected];))

Sept 18 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA LTD - FDA CONDUCTED INSPECTION AT NATCO PHARMA IN KOTHUR, HYDERABAD

• NATCO PHARMA LTD - RECEIVES EIR CLASSIFYING FACILITY AS 'VAI'

Source text: ID:nBSE8nbfJZ

Further company coverage: NATP.NS

(([email protected];))

** Shares of Natco Pharma NATP.NS down 0.7% at 903 rupees, while Nifty Pharma index up 1.2%

** Earlier was at 871 rupees, its lowest level since June 27

** Co reported 28.1% y/y fall in Q1 consol net profit as expenses rose

** Co says business faced pricing pressure in U.S. product portfolio, incurred increased R&D expenses on account of high value projects

** Average rating by 8 analysts is "hold"; median PT is 1,040.5 rupees - data compiled by LSEG

** YTD, NATP down 35.1% vs 6.7% fall in Nifty Pharma index

($1 = 87.6138 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

July 23 (Reuters) - Natco Pharma Ltd NATP.NS:

• TO BUY 51.6 MILLION SHARES OF ADCOCK INGRAM

• TOTAL INVESTMENT COST ABOUT 20 BILLION RUPEES

• TO INCORPORATE SUBSIDIARY IN SOUTH AFRICA WITH 21 BILLION RUPEES INVESTMENT

Source text: ID:nNSE4wrn0P

Further company coverage: NATP.NS

(([email protected];;))

** Shares of Natco Pharma NATP.NS down nearly 2% to 897 rupees

** Drugmaker says U.S. FDA inspected its Hyderabad facility and noted "one observation"

** Co did not elaborate on the observation, but said it was "procedural" and that it was confident it could address it comprehensively

** Stock, on avg, rated "hold" with median PT 935.50 rupees - data compiled by LSEG

** YTD stock down 36%

(Reporting by Hritam Mukherjee in Bengaluru)

(([email protected];))

** Shares of Natco Pharma NATP.NS rise 2.3% to 881.95 rupees

** Pharmaceuticals co's Q4 consol net profit rises 5.3% Y/Y to 4.07 bln rupees ($47.6 mln)

** Q4 revenue jumps 14.3% Y/Y, while expenses rose 23.5%

** Trading vols at 1.5 mln shares, 1.3x the 30-day average

** NATP down ~36% YTD

($1 = 85.4500 Indian rupees)

(Reporting by Vijay Malkar)

(([email protected];))

April 8 (Reuters) - Natco Pharma Ltd NATP.NS:

• NATCO PHARMA LTD - DELHI HIGH COURT DENIES ROCHE'S INJUNCTION PLEA AGAINST NATCO

• NATCO PHARMA LTD - UPDATES ON LEGAL PROCEEDINGS FOR RISDIPLAM LAUNCH IN INDIA

• NATCO PHARMA LTD - ROCHE APPEALS DECISION, APPELLATE BENCH DIRECTS STATUS QUO

• NATCO PHARMA LTD - PRICES RISDIPLAM AT 15,900 RUPEES MRP

• NATCO PHARMA LTD - TO OFFER DISCOUNT ON RISDIPLAM THROUGH PATIENT ACCESS PROGRAMME

• NATCO PHARMA: INTENDS TO LAUNCH RISDIPLAM AFTER CLARITY FROM APPELLATE BENCH, WHICH IS EXPECTED SHORTLY

Source text: ID:nBSE1wdNMH

Further company coverage: NATP.NS

(([email protected];))

March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.

Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:

NOVO NORDISK

The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.

The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.

Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.

SUN PHARMA

Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.

The drugmaker said earlier this month it expects to launch the drug in the next four to five years.

BIOCON

Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.

ZYDUS LIFESCIENCES

India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.

CIPLA

Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.

Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.

DR. REDDY'S

India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.

LUPIN

India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.

NATCO, MANKIND PHARMA, AUROBINDO PHARMA

Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.

Reuters was not able to independently verify the reports.

(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

(([email protected];))

** Shares of India's Natco Pharma NATP.NS drop 16.5% to 1017 rupees, marking their biggest intraday loss since debut

** The drugmaker's Q3 consol net profit fell 37.5% y/y, while rev dropped 37.4% y/y

** Stock sees steepest fall since June 5, 2024, set for fifth straight session of losses, if current trend holds

** NATP stock has lost ~27% so far in 2025

(Reporting by Yagnoseni Das in Bengaluru)

(([email protected];))

Feb 12 (Reuters) - Natco Pharma Ltd NATP.NS:

• DIVIDEND 1.5 RUPEES PER SHARE

• DEC-QUARTER CONSOL NET PROFIT 1.33 BILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.75 BILLION RUPEES

Source text: [ID:]

Further company coverage: NATP.NS

(([email protected];;))